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ABSTRACT
The diagnosis of solid pseudopapillary neoplasms (SPNs) is challenging because 
some SPNs share many similar morphological and immunohistochemical features 
with other pancreatic neoplasms. In this study, we investigated potential diagnostic 
markers of SPN. 
Based on the SPN-specific upregulated genes from a previous DNA microarray 
and proteome study, we selected six immunohistochemical markers [beta-catenin, 
androgen receptor (AR), lymphoid enhancer-binding factor 1 (LEF1), transcription 
factor for immunoglobulin heavy-chain enhancer 3 (TFE3), fused in sarcoma (FUS), 
and WNT inhibitory factor 1 (WIF-1)]. We also evaluated the Ki-67 proliferative index 
to investigate its associations with prognosis. To validate these markers, we studied 
91 SPNs as well as 51 pancreatic ductal carcinomas (PDC) and 48 neuroendocrine 
tumors (NET) as controls.
We found frequent and diffuse nuclear expressions of β-catenin (98.9%), AR 
(81.3%), LEF1 (93.4%), TFE3 (74.7%), FUS (84.6%), and cytoplasmic expression 
of WIF-1 (96.7%) in SPNs. In contrast, PDCs and NETs showed no expression. (P < 
0.001). When beta-catenin, LEF1, and TFE3 staining were combined, the sensitivity 
and specificity were 100% and 91.9%, respectively. Four (4.4%) SPNs showed distant 
metastasis and these tumors were associated with a relatively high Ki-67 proliferative 
index (≥ 5%; P = 0.013).
We identified LEF1, TFE3, and AR as putative diagnostic markers of SPN, auxiliary 
to β-catenin. Incorporated into an immunohistochemical panel, these markers could 
be beneficial to distinguish SPN from PDC and NET. In addition, we suggest that the 
Ki-67 proliferative index can be a predictive marker of metastasis in SPNs.
INTRODUCTION
Among pancreatic tumors, solid pseudopapillary 
neoplasm (SPN) is very rare and comprises only 1–3% of 
primary pancreatic tumors. In spite of its clinical rarity, the 
clinical and pathologic findings are well recognized. SPN 
is composed of poorly cohesive monomorphic epithelial 
cells that form solid, pseudopapillary structures, and it 
occurs predominantly in young women [1].
SPNs are genetically characterized by somatic 
mutations in exon 3 of CTNNB1, which encodes β-catenin 
[2, 3]. In addition, the molecular regulatory networks 
of SPN have recently been well-characterized [4-7]. 
Through an integrative analysis of mRNA, microRNA, 
and proteome expression profiles, we have identified many 
(> 1,000) SPN-specific upregulated genes, specifically 
activated Wnt/β-catenin, Hedgehog, and androgen 
receptor (AR) signaling pathways [6, 8].
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However, there are several unresolved issues in 
SPNs. First, putative diagnostic immunohistochemical 
markers are necessary. The pathologic diagnosis of SPNs 
is usually made using a combination of histologic and 
immunohistochemical markers, including beta-catenin, 
CD10, chromogranin, and E-cadherin [1, 9, 10]. Diffuse 
cytoplasmic and nuclear localization of β-catenin is 
almost always found in SPN, and these findings are 
helpful in the diagnosis of SPNs. Nevertheless, some 
SPNs are histologically and immunohistochemically 
similar to pancreatic neuroendocrine tumors (NETs), 
and nuclear localization of β-catenin can also be found 
in some pancreatic ductal adenocarcinomas (PDCs) and 
NETs. Second, there are still no definite prognostic and 
diagnostic criteria for predicting the malignant behavior of 
SPNs. Although most SPNs have low malignant potential 
and can be cured using surgical resection [11-13], it has 
been reported that up to 20% of SPNs showed recurrence 
or distant metastasis [11-16].
In this study, we selected several 
immunohistochemical markers from the SPN-specific up-
regulated genes and validated their diagnostic usability 
in SPNs. Additionally, we investigated clinicopathologic 
parameters associated with the malignant behavior of 
SPNs. 
RESULTS
Clinicopathologic characteristics of SPN
The basic clinicopathologic findings are listed in 
Table 1 and Figure 1. Sixty-one patients (67.0%) were ≤ 
40 years old (median, 34 years old; range, 8–67 years), 
with a predominance of women (75, 82.4%). The tumor 
size varied from 1 to 16 cm (average, 4.7 cm). Six (6.6%) 
tumors measured more than 10 cm. More than 80% of 
Figure 1: Histologic features (H & E stain) of SPNs. A. Infiltrative and B. expanding border of tumor (A and B, each original 
magnification x12.5). C. Pleomorphism and mitosis (original magnification x100). D. Lymphovascular invasion (original magnification 
x40). E. Perineural invasion (original magnification x100). F. Liver metastasis (original magnification x40).
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the tumors had at least a focally infiltrative border (73; 
80.2%, Figure 1A) and 40 (44%) showed peripancreatic 
adipose tissue invasion. Cellular pleomorphism (Figure 
1C) was observed in 6 (6.6%) cases and mitoses were 
found in up to 2/10 high-power fields (HPFs) in 4 (4.3%) 
cases. Calcification and extensive hemorrhage/necrosis 
were present in 38 (43.6%) and 25 (27.5%) of tumors, 
respectively. Small cytoplasmic hyaline globules, foamy 
histiocytes, cholesterol clefts, and myxoid stromal 
changes were also observed. Three cases (3.3%) showed 
lymphovascular invasion (Figure 1D) and lymph nodes 
metastasis, respectively. Perineural invasion (Figure 1E) 
was a relatively frequent finding in 47 (51.6%) cases. 
Distant metastasis occurred in 4 (4.4%, Figure1F) patients 
and recurrence developed in 3 (3.3%) patients. 
The rim of most SPNs is known to be infiltrative. 
However, since some SPNs show totally expanding 
borders, we examined whether clinicopathologic 
parameters differ depending on whether the margin of 
tumor invades surrounding parenchyma. When the border 
Table 1: Clinicopathologic characteristics of 91 SPNs
Table 2: Expression pattern of 6 markers in SPN
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Figure 2: Representative immunohistochemical results of SPNs. Beta-catenin (A1, negative and A2, strong positive), AR (B1-
B3), LEF1 (C1-C3), TFE3 (D1-D3), and FUS (E1-E3) show nuclear expression. WIF-1 (F1-F3) show cytoplasmic expression. Sub-
number indicates weak (1), moderate (2), and strong (3), respectively. Original magnification x100.
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of SPNs was divided into at least focally infiltrative pattern 
and totally expanding pattern, male sex (p = 0.035), 
smaller tumor size (p < 0.001), non-extensive hemorrhage 
and/or necrosis (p = 0.001), and frequent perineural 
invasion (p = 0.034) were found in the infiltrative SPNs 
(Table 1). We also found that SPNs in male patients had 
a lower incidence of hemorrhage and/or necrosis, more 
frequent infiltrative tumor borders, and peripancreatic 
invasion (Supplementary Table 2). They also showed a 
tendency toward more frequent lymph node metastasis (p 
= 0.079).
Immunohistochemical expression in SPN, PDC, 
and NET
The results of the immunohistochemical analysis of 
91 SPNs, 51 PDCs, and 48 NETs are shown in Table 2. 
Beta-catenin showed diffuse membranous expression in 
normal pancreatic tissue and AR was expressed in some of 
the normal pancreatic ductal epithelium. FUS and WIF-1 
showed occasional staining in the cytoplasm of pancreatic 
ductal cells and acinar cells. LEF1 and TFE3 were not 
expressed in normal pancreatic tissue. 
In the SPNs, nuclear expressions of β-catenin 
(98.9%), AR (81.3%), LEF1 (93.4%), TFE3 (74.7%), 
and FUS (84.6%), and cytoplasmic expression of WIF-
1 (96.7%) were noted (Figure 2, p < 0.001). In contrast, 
PDCs and NETs showed no or occasional expression. 
Although some markers were positive in both SPNs and/
or PDCs and NETs, there was no case showing strong 
expression of these markers in PDCs and NETs. Two 
of the 3 cases that had undergone decalcification during 
processing showed no expression of any of the markers, 
except for WIF-1 (weak) and β-catenin (moderate). 
After evaluating the diagnostic significance of 
these markers in pancreatic tumors, we described the 
sensitivity and specificity in Table 2 and Figure 3. Based 
on these findings, we concluded that LEF1, TFE3, and 
AR could be used as putative diagnostic markers of SPN. 
When β-catenin, LEF1, and TFE3 staining results were 
combined, the sensitivity and specificity were 100% and 
91.9%, respectively.
We also evaluated the relationship between the 
clinicopathologic findings and the expression of these 6 
markers. Among them, AR was more frequently expressed 
in male patients (p = 0.035). However, there were no other 
significant correlations between the expression of other 
markers and clinicopathologic parameters. 
A high Ki-67 proliferative index is associated with 
metastatic SPN
In our SPN cohort, distant metastasis was noted 
in 4 (4.4%) cases. The sites of metastasis were the liver 
(3, 3.3%; Figure 4B) and peritoneum (1, 1.1%). The Ki-
67 proliferative index was correlated with metastasis 
(p = 0.013, Table 3 and Figure 4A). Univariate logistic 
regression analysis revealed that lymphovascular invasion 
(OR = 21.75; p = 0.030), lymph node metastasis (OR 
= 22.50; p = 0.028), and a Ki-67 proliferative index of 
more than 5% (OR = 18.75; p = 0.014) were statistically 
significant risk factors for distant metastasis. The three 
recurred SPNs were associated with a larger tumor size (> 
5cm, p = 0.043), as well as a Ki-67 proliferative index of 
Figure 3: Sensitivity and specificity of six immunohistochemical markers for the diagnosis of SPN. When beta-catenin, 
LEF1, and TFE3 are combined, the sensitivity and specificity are 100% and 91.9%, respectively.
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more than 5% (p = 0.004). In univariate logistic regression 
analysis, lymphovascular invasion (OR = 44.00; p = 
0.017) and lymph node metastasis (OR = 45.50; p = 0.011) 
were statistically significant risk factors for recurrence. 
However, nuclear pleomorphism (Figure 4C), mitotic 
count, perineural invasion, peripancreatic extension, and 
infiltrative tumor borders were not associated with distant 
metastasis or recurrence.
DISCUSSION
At present, the pathologic diagnosis of SPN is based 
on histologic and immunohistochemical characteristics. 
SPN is composed of small monomorphic cells with clear or 
eosinophilic cytoplasm that form solid or pseudopapillary 
structures with poor cohesion. Mutations in exon 3 of the 
β-catenin gene have been identified in the majority of 
SPNs [2, 3] and diffuse nuclear expression of β-catenin is 
Table 3: Relationship between Ki-67 labeling index and metastasis/recurrence 
Figure 4: Ki-67 proliferative index and representative cases of SPNs with metastasis. Ki-67 proliferative index is related 
to distant metastasis (A, p = 0.013). Gross features of primary SPN (B1) and metastatic SPN in the liver (B2). H & E appearances 
metastatic SPN (B3, original magnification x40) and relatively high Ki-67 proliferative index (8.9%; B4, original magnification x400). 
Gross features of non-metastatic SPN (C1) may have pleomorphism (C2, original magnification x100) or peripancreatic extension (C3, 
original magnification x40), but show relatively low Ki-67 proliferative index (1.5%; C4, original magnification x400). 
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known to be a characteristic feature used in the diagnosis 
of SPN. Other diagnostic markers include E-cadherin 
(loss) [9, 17, 18], CD10 [19], alpha-1-antitrypsin [19], 
chromogranin (negative) [9, 16], CD99 (dot-like pattern) 
[20], beta form of estrogen receptors [21], galectin 3 [21], 
KIT [22], DOG1 [23], FLI-1 [24], and alpha-Methylacyl-
CoAracemase (AMACR, P504S) [25]. However, a 
confirmatory diagnosis of SPN is still challenging because 
SPN shares many morphological and immunophenotypical 
features with other pancreatic tumors, especially PDCs and 
NETs. In this study, we aimed to identify additional and 
putative diagnostic markers of SPN based on upregulated 
genes analyzed using mRNA expression profiling [6] and 
availability of antibodies. 
We demonstrated that the combination of several 
immunohistochemical markers enhanced the diagnostic 
accuracy of SPN. We initially selected 6 markers and 
found frequent and strong nuclear expression of beta-
catenin, AR, LEF1, TFE3, and FUS, and cytoplasmic 
expression of WIF-1 in SPNs. All 6 markers showed 
expression differences between SPNs and other pancreatic 
tumors. Although some markers were positive in both 
SPNs and/or PDCs and NETs, strong expression of 
these markers was not found in any PDCs or NETs. Our 
results confirmed that beta-catenin is the most sensitive 
(98.9%) and specific (97%) marker for SPN. Additionally, 
we demonstrated that 3 putative markers (LEF1, TFE3, 
and AR) showed high rates of sensitivity and specificity. 
When beta-catenin, LEF1, and TFE3 were combined, 
the sensitivity and specificity were 100% and 91.9%, 
respectively. Based on these findings, we suggest that 
LEF1, TFE3, and AR are useful for the diagnosis of SPN, 
and the combination of these markers with beta-catenin is 
helpful to improve their sensitivity and specificity in the 
diagnosis of SPNs. 
LEF1 is a member of the lymphoid enhancer-
binding factor 1/T-cell factor (LEF1/TCF) complex [26]. 
It interacts with mutant CTNNB1 and act as a regulator 
of the Wnt/CTNNB1 signaling pathway [26, 27]. It 
has been reported to be upregulated in SPNs compared 
with normal pancreatic tissue [6], PDCs, and NETs [7]. 
Singhi et al. [28] have demonstrated diffuse nuclear LEF1 
overexpression in 27 SPNs with high sensitivity and 
specificity. We observed similar results in a larger cohort. 
TFE3 is a member of the microphthalmia (MiT) 
family of transcription factors, which is composed of 
MITF, TFE3, TFEB, and TFEC. MiT transcription 
factors form homodimers or heterodimers that bind 
target promoters and act as regulators of melanocyte 
development, cellular proliferation, survival, motility, 
and metabolism, which are deregulated during oncogenic 
processes [29, 30]. The MITF/TFE3 family has also 
been shown to bind and enhance the activity of the LEF1 
protein, and may promote propagation of Wnt signals 
in many cell types [31]. TFE3 also had been reported 
to interact with AR and FUS in SPNs based on gene 
regulatory network analysis, and it has also been suggested 
as a novel biomarker of SPNs [7]. 
AR is associated with cell cycle regulation and 
with the AR signaling pathway, which is activated in 
SPN [6, 7]. Moreover, codon changes and codon deletion 
mutations in AR have been found using whole exome 
sequencing, which also reveals its close relationship 
with CTNNB1 signaling [32]. Recent studies have aimed 
to identify gene regulatory networks in SPN and have 
found that CTNNB1, LEF1, AR, and TFE3 interact with 
each other by diverse pathways [6, 7]. These findings 
indicate that CTNNB1, LEF1, AR, and TFE3 are closely 
interrelated with each other. 
In this study, we aimed to identify useful 
biomarkers for predicting the malignant behavior of 
SPN. There remains a lack of consensus of the criteria 
for “malignant” SPN. The concerning features, including 
perineural invasion, vascular invasion, or deep infiltrative 
growth, that are commonly found in other malignant 
neoplasms do not indicate malignant behavior in SPNs 
[1]. Consequently, all SPNs are presently classified as 
low-grade malignant neoplasms. For these reasons, 
we considered distant metastasis and recurrence as 
decisive malignant features of SPN. Several studies 
have also failed to demonstrate significant impacts of 
certain features that can predict metastasis or recurrence; 
however, an undifferentiated carcinoma component, a 
larger tumor size (> 8cm), microscopic malignant features 
(such as cellular atypia), pleomorphism, capsule invasion, 
peripancreatic tissue invasion, perineural invasion, 
lymphovascular invasion, and a high mitotic rate have 
all been suggested as risk factors for recurrence [12, 
14-16]. Despite this, we could not find any correlation 
between metastasis and clinicopathologic parameters, 
including nuclear pleomorphism, mitotic count, perineural 
invasion, peripancreatic extension, an infiltrative tumor 
border, and our putative biomarkers. For recurrence, 
a larger tumor size (> 5cm) was the only correlated 
factor. We evaluated the association between our 
immunohistochemical results and the malignant behavior 
of SPN, and found no relationship. We also performed 
Ki-67 immunohistochemistry and showed that SPNs 
with a KI-67 proliferative index of more than 5% were 
significantly associated with malignant behavior. A high 
proliferative index using Ki-67 immunohistochemistry 
has been associated with aggressive biological behavior 
of SPNs [14, 15]. We therefore suggest that close follow-
up is needed in patients with a Ki-67 proliferative index 
of more than 5%. 
In summary, we found that LEF1, TFE3, and AR 
were putative diagnostic markers of SPN auxiliary to 
β-catenin. Incorporated into an immunohistochemical 
panel, they could be beneficial to distinguish SPN from 
PDC and NET. In addition, we suggest that the Ki-
67 proliferative index could be a predictive marker of 
metastasis in SPN.
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MATERIALS AND METHODS
Case selection
Ninety-one formalin-fixed, paraffin-embedded 
(FFPE) specimens of SPN were obtained from the archives 
of the Department of Pathology, Yonsei University, Seoul, 
Korea and from the Liver Cancer Specimen Bank of the 
National Research Resource Bank Program of the Korean 
Science and Engineering Foundation of the Ministry of 
Science and Technology; the cases were encountered 
between 1999 and 2016. From consecutive cases of 
surgically resected pancreases, 51 PDCs were retrieved 
from 2009 to 2011 and 48 NETs were obtained from 2009 
to 2015. Hematoxylin and eosin (H&E)-stained slides 
of all cases were reviewed. Histologic diagnosis of SPN 
was made based on microscopic features and one or more 
immunohistochemical markers including beta-catenin, 
CD10, E-cadherin, and chromogranin [1].
Tissue microarray construction
Ninety-one cases of SPN, 51 of PDC, and 48 of 
NET were used for tissue microarray (TMA) construction 
using FFPE samples. A representative area of each case 
was selected under the microscope. Core tissues (3 
mm in diameter) were taken from the individual FFPE 
blocks (donor blocks) and arranged in recipient paraffin 
blocks (tissue array blocks) using a trephine apparatus. 
Thirty-eight SPNs were selected and examined using 
conventional whole sections to rule out intra-tumoral 
heterogeneity. 
Antibody selection and immunohistochemistry
In our previous study, we found 2,026 up-regulated 
genes in SPNs compared with non-neoplastic pancreas. 
Among them, 1,119 genes were exclusively up-regulated 
in SPNs compared to PDCs and NETs. Beta-catenin, AR 
and WNT inhibitory factor 1 (WIF-1) have been identified 
by western blotting and immunohistochemical analysis 
[6]. Beta-catenin and fused in sarcoma (FUS) have also 
been identified as overexpressed proteins in our previous 
proteome expression profiling study of SPN [8]. We 
chose lymphoid enhancer-binding factor 1 (LEF1) and 
transcription factor for immunoglobulin heavy-chain 
enhancer 3 (TFE3), which were associated with Wnt 
signaling pathway. Therefore, immunohistochemistry was 
performed with six commercially available antibodies to 
these proteins (Beta-catenin, AR, WIF-1, FUS, LEF1, and 
TFE3).
Immunohistochemistry was conducted on 4-μm 
TMA tissue sections by a Ventana Bench Mark XT 
Autostainer (Ventana Medical Systems, Tucson, 
AZ, USA). Details of the tested primary antibodies 
are shown in Supplementary Table 1. The pattern of 
immunohistochemical staining was examined by intensity 
and area (%) as follows; negative (no staining or staining 
of less than 5% of tumor cells), weak positive (faint 
protein expression in 5%–30% of tumor cells), moderate 
positive (faint protein expression in > 30% of tumor cells 
or definite protein expression in less than 30% of tumor 
cells), and strong positive (definite protein expression in > 
30% of tumor cells) [9, 20, 24]. 
We also evaluated Ki-67 proliferative index using 
whole section slides to investigate its associations with 
prognosis. For calculating Ki-67 proliferative index (Ki-
67 positive tumor cells/total counted tumor cells, %), each 
tumor slide was manually scanned with a microscope at × 
20 objective, and the area of greatest Ki67 positivity (hot 
spot) was selected for photography. Colored image of the 
hot spot was captured, and Ki67-negative and -positive 
tumor cells were marked in different colors. At least 
500 tumor cells were counted. Pale staining nuclei were 
ignored during counting [33].
Statistical analyses
Comparison of qualitative variables between 
groups was performed using the chi-square or Fisher’s 
exact test. The diagnostic sensitivity and the specificity 
for each of the markers individually, as well as in 
different combinations, were calculated. Using a logistic 
regression model, univariate analysis was conducted and 
odds ratios were estimated to assess predictive markers 
for distant metastasis. Two-sided P-values of less than 
0.05 were considered statistically significant. Statistical 
analyses were performed using IBM SPSS 22 software 
for Windows (IBM Corp, New York, USA).
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